Belgium· BE-AMP-SAM303195-00

Rasilez 300 mg

A aliskiren product containing aliskiren hemifumarate, registered in Belgium by Noden Pharma DAC. The same ATC class is registered in 13 of our 19 countries.

ATC C09XA02

Checked against FAMHP / AFMPS (Belgium) on September 26, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about aliskiren hemifumarateAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Aliskiren is registered in 13 of 19 countries.

Countries holding a registration under ATC C09XA02 (aliskiren), each read from that country’s own register.

This record: Belgium, from FAMHP / AFMPS (Belgium)
9 of them publish a price we can compare per daily dose

Search aliskiren products by name

Aliskiren · ATC C09XA02

13 / 19 countries

Belgiumprice
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Italyprice
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of aliskiren costs, country by country.

Normalised to the WHO defined daily dose (0.15 g), the median price runs from $0.95 in Italy to $3.43 in United States — a ×3.6 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown
US figures are pharmacy acquisition cost (CMS NADAC), not retail

Open the full comparison — free account Drug prices for market access

Aliskiren · price per daily dose (0.15 g)

USD · FX 28 Sept 2026

US United States$3.43 (acquisition cost)
IT Italy$0.95

Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)

Active substance: Aliskiren Hemifumarate
Manufacturer: Noden Pharma DAC
Country: Belgium (BE)
ATC code: C09XA02
ATC class: Aliskiren
Defined daily dose: 0.15 g, O
Reimbursed: Not published by this register
Source register: FAMHP / AFMPS (Belgium)
Last checked: September 26, 2026

Packs & prices · 3

be_apb
2473288
be_apb
0788562
be_apb
2473239

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

227 interactions on record for aliskiren.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check aliskiren against other medicines How interaction checks work

Aliskiren · interactions on record

227 records

1 severe
147 moderate
26 info

Most severe, free to view

CiclosporinL04AD01severe
ClotrimazoleA01AB18moderate
AprepitantA04AD12moderate
RolapitantA04AD14moderate

53 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Aliskiren in 4 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All aliskiren products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/dd188c4f-4c6c-4799-87f1-03bb31fc0bb0
GET /v1/drugs/dd188c4f-4c6c-4799-87f1-03bb31fc0bb0?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Rasilez 300 mg",
  "name_fr": "Rasilez 300 mg",
  "name_nl": "Rasilez 300 mg",
  "amp_code": "SAM303195-00",
  "strengths": [
    "300.0000",
    "300.0000"
  ],
  "pack_count": 20,
  "substances": [
    "Aliskiren Hemifumarate",
    "Aliskiren"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Aliskiren",
  "authorisation_numbers": [
    "EU/1/07/405/011",
    "EU/1/07/405/012",
    "EU/1/07/405/013",
    "EU/1/07/405/014",
    "EU/1/07/405/015",
    "EU/1/07/405/016",
    "EU/1/07/405/017",
    "EU/1/07/405/018",
    "EU/1/07/405/019",
    "EU/1/07/405/020",
    "EU/1/07/405/031",
    "EU/1/07/405/033",
    "EU/1/07/405/032",
    "EU/1/07/405/035",
    "EU/1/07/405/034",
    "EU/1/07/405/037",
    "EU/1/07/405/036",
    "EU/1/07/405/039",
    "EU/1/07/405/038",
    "EU/1/07/405/040"
  ]
}

API reference MCP server Plans

See everything about aliskiren.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console